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The convincing background of the recent studies, investigating the different potentials of platelet-rich plasma, offers the clinician
an appealing alternative for the treatment of cartilage lesions and osteoarthritis. Recent evidences in literature have shown that PRP
may be helpful both as an adjuvant for surgical treatment of cartilage defects and as a therapeutic tool by intra-articular injection
in patients affected by osteoarthritis. In this review, the authors introduce the trophic and anti-inflammatory properties of PRP
and the different products of the available platelet concentrates. Then, in a complex scenario made of a great number of clinical
variables, they resume the current literature on the PRP applications in cartilage surgery as well as the use of intra-articular PRP
injections for the conservative treatment of cartilage degenerative lesions and osteoarthritis in humans, available as both case series
and comparative studies.The result of this review confirms the fascinating biological role of PRP, althoughmany aspects yet remain
to be clarified and the use of PRP in a clinical setting has to be considered still exploratory.
1. Introduction
Platelets are one of the smallest structures among the cir-
culating cells in blood; they are anucleate, therefore unable
to replicate, their diameter is between 2 and 4 𝜇m, and they
consist of cytoplasm and vesicles and survive no more than
10 days in circulation [1].
Yet, they are in continual “call of duty” because inside
them lies one of the most powerful reservoirs of factors
responsible for tissue repair. Indeed, these little “bag of
molecules” are essential for the regenerative process in
human. Recent literature has shown, in the plateletmicrovesi-
cles and exosomes [2], the presence of prepackaged multiple
growth factors (GFs) in an inactive form. The most relevant
are platelet-derived growth factor (PDGF), transforming
growth factor beta (TGF-beta), fibroblast growth factor
(FGF), insulin-like Growth Factor 1 (IGF-1), Connective
Tissue Growth Factor (CTGF), Epidermal Growth Factor
(EGF), and Hepatocyte Growth Factor (HFG) [3, 4]. In
platelets microvesicles, different microRNAs [5] involved in
mesenchymal tissue regeneration [6–8] are also present and
some of them, as microRNA-23b, has been hypothesized to
be strictly involved in differentiation of MSC into chondro-
cytes [9] or, as miRNA210, has been already proposed as a
therapeutic alternative to increase ligament healing bymeans
of intra-articular injections in a small animal model [10].
Moreover, clear anti-inflammatory properties of platelet
concentrates have been investigated as an associate effect in
promoting tissue healing. This aspect could be a mainstay
when dealing with articular cartilage lesions. It is known
that an inflammatory response of appropriate magnitude
and timing is essential for tissue repair as the majority of
mesenchymal repair arise from a “controlled” inflammation.
In this regard, lowering the inflammation in the synovial tis-
sue would lead to a reduction of matrix-metalloproteinases,
which are cartilage-matrix degrading enzymes [4].
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The in vitro and preclinical evidences are the premises
for the fascinating trophic properties of PRP [3, 11] that, with
regards to articular cartilage, may be resumed in
(i) the presence of specific chondrogenic growth factors
such as PDGF (that may stimulate proliferation and
collagen synthesis), TGF-beta (that may enhance
chondrocyte synthetic activity, matrix production,
and cell proliferation and decreases the catabolic
activity of IL-1), and FGF (that promotes different
anabolic pathways);
(ii) the chemotactic migration ofmesenchymal stem cells
(MSC) and human subchondral progenitor cells, by
mechanisms that may involve a synergistic action of
TGF-beta and FGF [12];
(iii) the stimulation of the proliferation rate of MSC,
independently from donor age [13, 14];
(iv) the differentiation of MSC and surrounding cells
toward a chondrogenic lineage [12, 15]: this effect
has also been demonstrated in vitro with autologous
human peripheral blood stem cells;
(v) the anti-inflammatory action of PRP [4, 16, 17];
(vi) a hypothesizable antiapoptotic effect, by means of
inhibition of apoptotic related factors (i.e., downreg-
ulation of programmed cell death protein 5 by IGF-1)
[18].
Therefore, during the last 10 years, this convincing back-
ground of basic science studies about PRP has offered the
clinician a promising opportunity of a new approach to the
treatment of cartilage lesions and osteoarthritis.
In a clinical setting, autologous PRP may be defined as a
platelet concentration product containing at least 200% of the
peripheral blood platelet count. It can be produced essentially
through 3 different methods:
(i) blood filtration and plateletpheresis, that allow
obtaining PRP products with high concentrations of
human platelets and platelet-derived growth factors
and low numbers of contaminating leucocytes, but
implying high costs [19];
(ii) centrifugation by a “single-spinning” that has low
costs and allows for a concentration of platelets up to
3 times that of baseline level, avoiding the presence of
white cells;
(iii) centrifugation by a “double-spinning,” from which a
higher concentration of platelets (up to 8 fold the
baseline level) may be achieved, together with the
presence of a high content of leukocyte.
Following these basic concepts, 4 categories of final products
of platelet concentrates can be identified for clinical purposes,
as suggested by Dohan Ehrenfest et al. [20].
(1) Pure PRP, with a low content of leukocyte (P-PRP)
or leukocyte-poor platelet-rich plasma. It is a preparation
without leukocytes and with a low-density fibrin network
after activation. It can be employed as liquid solution or in an
activated gel form and it can be injected intra-articularly or
simply positioned during the gelling phase on a skin wound.
It can be prepared by plasmapheresis, but for a wide clinical
application it may result unpractical. Anitua et al. [21] have
proposed a method that implies a centrifugation at 580 g for
8 minutes of the extracted blood and a separation of the
plasma fractions by pipetting. They have named the product
Plasma Rich in Growth Factors or Preparations Rich in
Growth Factors or EndoRet. The disadvantage is the manual
pipetting steps that may hamper the reproducibility of the
final product.
(2) Leukocyte rich PRP (L-PRP) is a product with leuko-
cytes and with a low-density fibrin network after activa-
tion and it is composed of a greater content of platelets
than that of pure PRP and a higher content of leukocytes.
Similarly to P-PRP, it can be used as an activated gel or
in a liquid form to be injected intra-articularly. It can be
produced by automated double centrifugation systems and
many commercial alternatives are available as Harvest Smart-
PreP (Harvest Technologies, Plymouth, MA, USA), Biomet
GPS III (Biomet Inc., Warsaw, IN, USA), Plateltex (Prague,
Czech Republic), or Regen PRP (RegenLab, Le Mont-sur-
Lausanne, Switzerland) [22].
In both P-PRP and L-PRP, the activated gel is formed
through activation of platelets and fibrinogen (that creates a
fibrin net) by different activating molecules (i.e., thrombin,
CaCl
2
). Once activated, platelets deliver nearly 70% of their
GFs within the first 10 minutes and within an hour most
of the stored GFs have been already secreted [23]. The
platelet-derived growth factors are firstly absorbed and then
released by the fibrin net that behaves in the same way as
the extracellular matrix does. So, in the PRP, a release kinetic
of the platelet GFs can be conceived. This kinetic depends
on the content of fibrin in the final product. This content
varies according to the individual platelets and fibrinogen
concentration and on the fibrin structure diversity created
by the different procoagulant enzymes that induce the gel
formation. These basic concepts allow explaining the length
of action of PRP, once delivered at the lesion site. As an
example, a recent study by Anitua et al. [24] showed that 70%
of the stored PDGF is released from a PRP gel formed by a
single slow centrifugation and CaCl
2
activation in a period of
3 days, while 70% of VEGF, 60% of HGF, and 60% of IGF-1 in
24 hours; then, the GF release usually reaches a plateau and
a slow secretion of the remaining content is completed up to
7-8 days.
A traditional activator of platelets is bovine or autologous
thrombin. Concerns about the tolerability of the bovine
products, alongwith some observations showing a fast release
of GFs and some adverse effects in presence of thrombin [25],
have suggested the use of different activators. Indeed, calcium
chloride, batroxobin, and collagen type I may be used, the
latter leading in vitro to a slower release of GFs compared to
thrombin. It is also possible the use of a nonactivated PRP that
may count on the activating effect of endogenous collagen (in
situ activation), although the liquid state would restrict the
clinical applicability. Moreover, to allow for a prolonged and
sustained release of GFs, a novel approach theorize the use of
common scaffolds (i.e., chitosan [26, 27]) as a carrier of PRP,
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and surprising results have been obtained with a prolonged
release of GFs up to 20 days.
(3) Pure platelet-rich fibrin (P-PRF or PRFM, platelet
rich fibrin matrix). This is obtained, firstly, by a slow cen-
trifugation (approximately 1000 g) in a separator gel, that
allows for the isolation of both the inactivated platelets
and fibrinogen-containing plasma from the packed red and
white cell fraction. Subsequently, a second centrifugation
at high speed (approximately 3500 g) is performed in the
presence of Ca (calcium chloride, CaCl
2
). CaCl
2
initiates the
clotting cascade and the precipitation of a fibrin scaffold,
thus obtaining the formation of a gel containing fibrin as a
stabilizer of the “platelet clot.” The end product is a platelet-
rich fibrin scaffold, which is stiffer than the conventional
PRP. It has a four-fold increment of platelets [28] and a
low content of leukocyte and has the shape of a moldable
tridimensional gel. A commercial alternative of P-PRF is
named Fibrinet PRFM (Platelet- Rich FibrinMatrix, Cascade
Medical, Wayne, NJ, USA).This gel can be sutured or pressed
in a defect site. It cannot be injected, due to the strongly
activated gel form. Therefore, due to the high content in
fibrin, this PRP formulation may release the platelet growth
factors in a more extensive period, up to 7 days, with a
high variability of the release kinetic. Indeed, an abundant
release of the GFs has been observed within the first day
and a gradual decrease of the release of the growth factors
thereafter, within 2 days for VEGF and PDGF and within 7
days for EGF and FGF [29].
(4) Leukocyte- and platelet-rich fibrin (L-PRF), similar
to the latter, but with high content of leukocyte. As P-
PRF, L-PRF is a strongly activated gel with a high-density
fibrin network and it cannot be injected. It has the form
of a solid material and it can be locally applied at the
lesion site. It was derived from a one-step centrifugation of
blood without anticoagulant and without blood activator.
A commercial product of L-PRF is the Intra-Spin L-PRF
(Intra-Lock Inc., Boca Raton, FL, USA). This is a simple and
inexpensive method and it allows producing large quantities
of product in a very short time. It has been widely used in oral
and maxillofacial surgery and, in orthopaedics, it has been
proposed to facilitate the rotator cuff repair [30].
In general, a high content of leukocyte has been associated
with antimicrobial activity, as studies have shown that L-
PRP has a negative effect on the growth of Staphylococcus
aureus and Escherichia coli in vitro [31]. A L-PRP is also
associated with a greater presence of catabolic cytokines as
matrix metalloproteinase-9 (MMP-9) and interleukin-1 beta
(IL-1beta) [32, 33] as well as a greater number of platelets. As
a consequence, a theoretical greater content of growth factors
like PDGF and TGF-beta is linked to L-PRP. Nevertheless,
an interesting study by Anitua et al. [34] has shown an
important decrease of the availability of VEGF after 3 days
of incubation and a decrease of PDGF release in L-PRP.
Moreover, in a recent preclinical (rabbit) [35] study, L-PRP
has been observed to cause greater inflammatory reactions
and more undesirable side effects than P-PRP following the
injection at the lesion site.
Therefore, for a proper clinical use, it is of primary
importance to know what type of preparation will be created
by a specific commercial system, to allow for the correct
choice of a suitable final formulation. Nevertheless, for this
purpose, the presence of leukocyte in regard to the treatment
of cartilage lesions should not be viewed straightforwardly as
a “foe,” but as a still debated issue. Indeed, in a recent in vitro
study by Cavallo et al., a preparation of L-PRP was able to
promote chondrocyte proliferation as well as a P-PRP at end
term of the culture and the production of hyaluronan was
greater with L-PRP compared to that of P-PRP [36]. More
studies are needed to determine the best PRP formulation
for the treatment of cartilage lesions and osteoarthritis in
humans.
In the perspective of a translation from “bench to bed-
side,” these observations suggest that a clinical application
of PRP for cartilage lesions and osteoarthritis has more
questions than answers and a great number of variables have
to be considered as:
(i) the interindividual differences in platelets and fibrin
concentration;
(ii) the different methods of PRP preparation [37];
(iii) the unpredictable individual response to a spe-
cific method; intraindividual variations have been
observed within the same method performed on
samples taken at a different time periods [38] and also
significant variations in PRP obtained from different
preparation systems have been described in a single-
donor model [39];
(iv) the storage of platelets: fresh PRP seems to better
preserve platelet function and GF-release compared
to freeze-thawed PRP; nevertheless, the use of fresh
PRP implies blood harvesting and PRP preparation
every time a PRP injection has to be performed,
while freeze-thawing would allow for a preservation
of multiple PRP samples from the same patient;
(v) the possible use of homologous PRP produced by a
blood bank; this alternative would reduce the bias
derived from the interindividual platelet differences
and would offer a single homogeneous and repro-
ducible product available for clinical use, similarly to
the blood transfusion concept; this method has been
adopted in different clinical settings, in example for
the cure of necrobiosis lipoidica in diabetic patients
with good results [40]; recently, the use of allogenous
PRP has been also proposed in literature for the treat-
ment of cartilage defects in humans; allogenous PRP
was used as a carrier for autologous culture expanded
bone marrow MSC in the pilot study of Haleem et al.
[41]; it may represent a potential opportunity in the
field of PRP application for cartilage repair.
In such a complex clinical landscape, some promising studies
have been completed in the last 10 years. Literature indicates
that the evidence of a valid effect of PRP for cartilage repair
is perceptible both for the treatment of cartilage lesions
by means of reconstructive surgery and for the treatment
of osteoarthritis by means of conservative intra-articular
delivery.
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2. PRP and Cartilage Surgery
A rationale for PRP application in cartilage surgery is sug-
gested by in vitro and preclinical experiences [11] due to the
trophic properties, the ability to help MSC to differentiate
toward cartilage and bone in an appropriate environment and
the anti-inflammatory capacity.
One of the first experiences came from the study of
Sa´nchez et al. in 2003 [42]. They treated a patient with osteo-
chondritis dissecans of the medial femoral condyle by means
of arthroscopic reattachment of the loose chondral body and
PRP injection between the crater and the fixed fragment.
They obtained a promising clinical result demonstrated by
magnetic resonance imaging (MRI).
Subsequently, PRP has been associated with the micro-
fracture technique to improve the cartilage repair. The pre-
clinical sheepmodel ofMilano et al. [43] offered a convincing
“proof of concept” of this intuition, advocating the use of
gel rather than a liquid preparation for this specific surgical
approach. In humans, this approach has been validated in
a recent randomized study by Lee et al. [44]. These authors
investigated the potential of PRP as an adjunct at the end
of the microfracture procedure for knee cartilage defects
up to 4 cm2 in patients older than 40 years of age. They
used a L-PRP and the process of preparation did not imply
the use of activator. PRP was injected in situ around the
microfracture holes after removal of arthroscopic fluid from
the joint, following the principle of the in situ activation.
Their outcomes were convincing with regards to the clinical
scores (IKDC and Lysholm) at 2 years and the second
arthroscopic view at a short time follow-up (4–6 months).
This was thought to be due to the double action of PRP in
enhancing bone marrow MSC migration and activation and
in reducing the inflammation and, subsequently, the pain at
the surgical site. These results propose PRP as a promoter of
healing process after microfracture. Moreover, theoretically,
they allow for broadening the indication of this technique to a
population older than 40 years of age, in whichmicrofracture
repair alone may become less efficient compared to younger
patients.
However, PRP may also be used postoperatively
with encouraging results. The recent comparative study
of Manunta and Manconi [45] proposed a protocol of
multiple L-PRP injections given at a short distance from the
microfracture procedures. The authors obtained at 1 year
similar results to that of the study of Lee, although their small
number of cases did not lead to a statistical significance.
Similar promising effects were as well obtained in treating
osteochondral talar lesion in the randomized, prospectively
designed study of Guney et al. [46]. They used a L-PRP
administered 6–24 hours postoperatively through the arthro-
scopic portal entry site. At amedium term follow-up (average
16 months), the authors observed better scores in the visual
analogue scale (VAS) scale, in the American Orthopaedic
Foot and Ankle Society (AOFAS) scoring system and in the
Foot and Ankle Ability Measure (FAAM), compared to that
of control cases. Thus, they sustained that an immediate
postoperative PRP injection may improve the functional
recovery of talar osteochondral lesions treated by microfrac-
ture technique.
PRP has been also locally applied by means of scaffolds,
following the principles of the acellular one-stage cartilage
repair. Several preclinical evidences have shown a positive
effect of PRP in association with different materials [47].
Nevertheless the experience of the Rizzoli group has rec-
ommended caution when using PRP in association with
their nanostructured three-layered scaffoldmade of collagen-
hydroxyapatite [48]. Overall, these preclinical observations
suggest that PRP seems to “make a difference” when com-
bined to scaffold with a simple tridimensional structure, as
a bilayer collagen matrix [49] or a microporous PLGA [50].
The positive influence of PRP may indeed be hampered by
the presence of scaffolds with more complex configuration
as the nanostructured membranes. These nanoscaffolds, per
se, would already lead to an improved osteochondral repair
through peculiar modalities like the chondrogenic effect of
the nanoparticles of hydroxyapatite [51, 52]. With regard to
that, recent clinical studies have proposed PRP in association
with collagen or synthetic implants, showing a positive effect
of PRP augmentation. In the first study, Dhollander et al. [53]
treated patellar cartilage defects by means of microfractures
with slow speed drilling. They covered the defect site with
a collagen I/III membrane, manually inserted a L-PRP gel
beneath the scaffold and named this technique “AMIC plus,”
a modification of the original AMIC (autologous matrix-
induced chondrogenesis) procedure. After a follow-up of
24 months, they obtained good results in terms of clinical
outcome.They observed improvement inKOOS (Knee injury
and Osteoarthritis Outcome Score), Tegner activity scale,
Kujala patellofemoral score, and VAS scale. The MRI evalua-
tion with the MOCART system showed an incomplete repair
with subchondral lamina, bone changes, and intralesional
osteophytes. Albeit confined in a low level of evidence,
these results are encouraging both for the effect of PRP for
enhancing cartilage repair and for the controversial treatment
of patellar chondral lesions. In the studies of Siclari et al.
[54, 55], polyglycolic acid- (PGA-) hyaluronan (HA) scaffolds
were soaked by a P-PRP and used to cover femoral and tibial
condyle defects previously treated with microfractures by
means of K-wire drilling (as in the Pridie technique). As an
adjunct, the tibial defect was stabilized by the PRP gelled by
calcium gluconate and thrombin additives, while the femoral
fixation was performed with small barbed polylactic acid
(PLA) nail. Clinical improvement was demonstrated by the
evidence of betterKOOS at 12months of follow-up, compared
to that of the preoperative period. This result was stable also
at 24 months. Biopsies taken from second look arthroscopies
at 18–24 months of follow-up suggested that the repair tissue
had some features of the hyaline articular cartilage. Even if
these studies lack a control group, their results suggested a
potential of PRP in association with a scaffold for one stage
treatment of chondral lesions.
The association with MSC is an alternative method of
applying the positive effect of PRP for the repair of cartilage
defects. In this convincing perspective, the PRP may directly
enhance the reparative properties of the MSC seeded at the
defect. In the pilot study of Haleem et al. [41], autologous
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bone marrow cells, previously expanded for 4 weeks, were
seeded in an allogeneic PRP. The PRP was obtained by
double centrifugation and mixed with fibrin glue, made by
fibrinogen and thrombin, to constitute platelet rich fibrin
glue. This stable scaffold was kept in situ by a periosteal flap.
The inoculum density of MSC was 2 × 106 cells/cm2. The
design of this study recalls the valiant works of Wakitani [56,
57]. Albeit the few cases treated, the clinical improvements,
the macroscopic results of two second-look arthroscopies at
12 months and the magnetic resonance images make this
study an interesting premise for future developments.
However, the strongest contribution to this approach
came from the group of Giannini. Both talar and knee
cartilage lesions were treated by a novel arthroscopic one-
stage approach consisting of a scaffold loaded with bone
marrow concentrate and platelet-rich fibrin gel (P-PRF).
The rationale of this method is the combination of the
positive effect of platelet growth factors and the synergistic
action of CD34+ and CD34− precursor cells harvested from
iliac crest bone marrow. In that, the evidence in literature
of the role of CD34+ precursor cells for cartilage repair
are multiple in vitro [58], in vivo in preclinical models
(rat, rabbit) [59, 60], and also in humans, as shown in
the pilot work of Saw et al. [61]. Moreover, no major cell
manipulation is involved in this technique and autologous
elements are utilized. All these features lead to a reproducible
and economic procedure with promising results, as shown by
Giannini et al. for talar osteochondral lesions [62–64]. The
authors distributed the bone marrow concentrate and the P-
PRF either by mixing with a porcine collagen powder or by
loading an esterified hyaluronic acid-derivative membrane.
The composite was placed at the lesion site after debridement
of cartilage fragments and pathologic subchondral bone and
it was stabilized by an additional amount of platelet-rich
fibrin gel. In the first case series, after 24 months of follow-
up, they observed an improvement in the AOFAS score and
a consistent repair tissue at MRI. Second-look arthroscopies
at 24 months showed a macroscopic aspect similar to that
of articular cartilage, with a histological staining positive for
SAFRANIN-0 and with collagen type II in the intermediate
and deep zone of the newly generated repair tissue. Better
results were found in smaller lesions (less than 2 cm2) and
in patients without previous surgery. They confirmed the
stability of their clinical results at 4 years of follow-up,
although a slight decline in the AOFAS scores was observed
between 24 and 48 months postoperatively [64]. The authors
compared also this technique with previously performed
cartilage repair procedures bymeans of open field autologous
chondrocyte implantation (ACI), using a periosteal flap as a
sealing for the cells, and arthroscopic ACI, in which the same
esterified hyaluronic acid-derivative membrane was used as
a scaffold [63]. This comparative retrospective study showed
a intriguing result: similar pattern of AOFAS improvement
was observed for the three groups at the end of the follow-
up (36 months) as well as comparable histological and MRI
findings. This suggests that the single-stage association of
bone marrow concentrate and the PRP may be as effective as
other regenerative techniques like the ACI for the treatment
of talar osteochondral lesions, with lower costs and less
invasivity for the patients. An analogous approach was used
by these authors to treat femoral condyle cartilage defects
[65]. They firstly implanted the esterified hyaluronic acid-
derivativemembrane, soakedwith bonemarrow concentrate,
at the previously debrided lesion site and, at the end of the
procedure, they applied the P-PRF onto the scaffold. Similarly
to the outcome in the ankle, they observed, after 2 years,
clinical (KOOS and IKDC score) and MRI improvement, as
well as a histological appearance of regenerated proteoglycan-
rich matrix in the middle and deep zones of biopsies taken
at 12 months. Their results were also confirmed at 3 years of
follow-up in a case series [66]. Again, these observations indi-
cate that the one-step approach with a combination of PRP
and bone marrow concentrate may represent an interesting
alternative among the different cartilage repair procedures.
The studies concerning PRP application in cartilage surgery
are summarized in Table 1.
Thus, considering the available literature, PRP seems to
positively influence the cartilage repair process. Nevertheless,
no clear evidence is yet available for ascertaining the exact
contribution of PRP with respect to the surgical treatments
performed alone. Indeed, the association of PRP with other
biological treatments, as the implantation of MSC or the
use of scaffold, and the lack of comparative studies have
hampered the possibility to define the specific role of PRP in
improving the outcomes. In the future, prospective clinical
trials will be certainly helpful in determining the basic rules
of using PRP in cartilage regenerative techniques.
3. PRP and Intra-Articular Injections for
Cartilage Pathology
Theconcept of a conservative treatment for cartilage degener-
ative lesions and osteoarthritis (OA) in humans by means of
the regenerative and anti-inflammatory potential of PRP has
been widely investigated. It represents an appealing approach
derived from the promising in vitro and preclinical evidences
[13], associated with low cost and minimally invasive proce-
dure (Figure 1).
Several case series (Table 2) and comparative trials
(Table 3) with different protocol regimens have shown a
positive effect of PRP, leading to an overall improvement
of the symptoms. The most common side effects reported
were pain at the site of injection, lasting for some minutes,
swelling and postinjective pain in the affected joint, that
usually subsided in few days [67] without hampering the end-
term PRP positive results.
In one of the first trials in 2010, Sampson et al. [68]
used L-PRP to treat 14 patients with knee OA by means
of 3 ultrasound-guided injections at 4 week intervals. They
observed pain and symptoms relief at the KOOS and at
the Brittberg-Peterson scores still after 12 months, although
no significant differences were observed in the ultrasound
measurement of the cartilage thickness during the first 6
months.
In a larger study group, Wang-Saegusa et al. [69] treated
261 patients with symptomatic OA of the knee. They used
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Table 1: Studies concerning PRP application in cartilage surgery.
PRP and cartilage surgery
Authors Year
Number of
cases
(age and
range in y)
Study Level ofevidence
Type of
PRP Procedure and observations Clinical results
Sa´nchez
et al. [42] 2003
1
(age 12) Case report IV /
Arthroscopic reattachment
of the loose chondral body
and PRP injection between
the crater and the fixed
fragment.
Excellent functional
outcome, rapid resumption
of symptom-free athletic
activity.
Haleem
et al. [41] 2010
5
(age 21–37) Case series IV L-PRP (?)
MSC seeded in a platelet
rich fibrin glue; femoral
condyle cartilage lesions
(size 3–12 cm2).
Improvement at 6 and 12
months postoperatively in
Lysholm and Revised
Hospital for Special Surgery
Knee (RHSSK) scores.
Giannini
et al. [63] 2010
25
(mean age
28 ± 9)
Retrospective
comparative
study
III P-PRF
Bone marrow concentrate
and P-PRF either by mixing
with a porcine collagen
powder or by loading a
esterified hyaluronic
acid-derivative membrane;
talar osteochondral lesions
(mean size >1.5 cm2).
Improvement in AOFAS
score from preoperatively
to 12 months and from 12 to
36 months.
Dhollander
et al. [53] 2011
5
(age 24–45) Case series IV L-PRP
PRP gel inserted beneath a
collagen I/III membrane
after the microfracture
procedure; patellar focal
cartilage lesions (size
1–3 cm2).
Improvement in VAS,
KOOS and Kujala
patellofemoral score at 1
and 2 years; no difference in
Tegner activity scale during
the 24-month follow-up.
Lee et al.
[44] 2013
24
(age 40–50)
Randomized,
prospectively
designed
study
II L-PRP
PRP injection at the end of
the microfracture
procedure for femoral
condyle cartilage defects up
to 4 cm2 of size.
Better improvements in
VAS and IKDC scores
compared to control group
at 2 years postop.
Guney et al.
[46] 2013
19
(age 18–63)
Randomized,
prospectively
designed
study
II L-PRP
PRP injection 6–24 h after
the microfracture
procedure for talar
osteochondral lesion
(diameter less than 20mm).
Better improvements in
VAS, AOFAS, FAAM
overall pain domain, and
FAAM 15-min walking
domain at 16 months
compared to control group.
Manunta
and
Manconi
[45]
2013 10(age 30–55)
Randomized
clinical study II L-PRP
3 PRP injections (1 week
after surgery, then at an
interval of 1 month); medial
femoral condyle cartilage
defects (Outerbridge II and
III).
Better improvement at 6
and 12 months in IKDC
score compared to control
group.
Giannini
et al.
[62, 64]
2009,
2013
49
(mean age
28 ± 9)
Case series IV P-PRF
Bone marrow concentrate
and P-PRF either by mixing
with a porcine collagen
powder or by loading a
esterified hyaluronic
acid-derivative membrane;
talar osteochondral lesions
(mean size 2 cm2).
Improvement in AOFAS
score from preoperatively
to 24 months, slight
decrease at 36 and 48
months; inverse
relationship at 24 months
between the area of the
lesion (< or >2 cm2) and
the AOFAS score and at 48
months between the time
from trauma to surgery and
the AOFAS score.
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Table 1: Continued.
PRP and cartilage surgery
Authors Year
Number of
cases
(age and
range in y)
Study Level ofevidence
Type of
PRP Procedure and observations Clinical results
Buda et al.
[65, 66]
2010,
2013
20
(age 15–50) Case series IV P-PRF
Hyaluronic acid membrane
filled with bone-marrow
concentrate; a layer of
P-PRF applied onto the
implanted material; femoral
condyle lesions ICRS III
and IV.
Improvement at 29 months
postoperatively in IKDC
and KOOS scores.
Siclari et al.
[54, 55]
2012,
2014
52
(age 31–65) Case series IV P-PRP
PGA-HA scaffolds soaked
by PRP to cover the defect
site previously treated by
microfracture procedure;
femoral and tibial condyle
cartilage lesions (size
1.5–5 cm2).
Improvement at 12 and 24
months postoperatively in
KOOS scores.
y = years; PRP = Platelet-Rich Plasma; MSC = Mesenchymal Stem Cells; P-PRP = Pure PRP, with a low content of leukocyte; L-PRP = Leukocyte rich PRP;
P-PRF = Pure Platelet-Rich Fibrin.
(a) (b)
(c) (d)
Figure 1: Preparation of PRP from peripheral blood sample; (a) blood aspiration; (b) transfer of patient blood into the PRP preparation
chamber; (c) final PRP product; (d) intra-articular PRP injection.
a P-PRP prepared following Anitua’s technique (PRGF,
“preparation rich in growth factors” or plasma-rich growth
factors or platelet rich growth factors) and administered
3 intra-articular injections of autologous PRGF at 2 week
intervals. Their results showed improvement after 6 months
in all 4 tests used, namely, the VAS, SF-36 Health Physical
parameters, WOMAC, and Lequesne Algofunctional Index.
Kon et al. [70] treated 91 patients with chondropathy or
knee OA with a regimen of 3 intra-articular injections of
L-PRP and follow-up of the patients for 12 months with
the IKDC and EQ VAS scores. They obtained 80% of
patients’ satisfactions and improvement of all scores from
basal values. Nevertheless, this study is the first that outlined
two fundamental aspects of this approach: (i) the correlation
between the worst outcomes and the older age of the patients
and the advanced OA and (ii) the decrease of the clinical
improvement after 6 months from the end of the treatment.
They also outlined inferior outcomes in the presence of
higher body mass index (BMI) and in female patients, while
previous surgery did not affected the results. These findings
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Table 2: Case series concerning PRP intra-articular injections for cartilage pathology.
PRP and intra-articular injections for cartilage pathology: case series
Authors Year
Number of
cases
(age and
range in y)
Study Level ofevidence
Type of
PRP Procedure and observations Clinical results
Sampson
et al. [68] 2010
14
(age 18–87)
Case
series IV L-PRP
3 L-PRP injections at
4-week interval;
Improvement at 52 weeks
from baseline in
Brittberg-Peterson VAS for
Pain—resting, Pain—moving,
and Pain—bent knee and in
KOOS for Pain and Symptom
Relief.
Kon et al.
[70] 2010
91
(age 24–82)
Case
series IV L-PRP
3 L-PRP injections at
3-week interval; before the
injection: Ca-chloride was
added to activate platelets;
knee articular damage:
grades 0–4 of
Kellgren-Lawrence scale.
Improvement at 6 and 12
months from baseline in
IKDC, objective and
subjective, and EQ VAS;
tendency of worsening
between 6 and 12 months.
Wang-
Saegusa
et al. [69]
2011
261
(mean age
48 ± 17)
Case
series IV P-PRP
PRGF obtained following
Anitua’s technique; 3
injections at 2-week
interval.
Improvement at 6 months
from baseline in VAS pain
score, Lequesne Index, SF-36
physical, WOMAC Index for
pain, stiffness and functional
capacity.
Filardo et al.
[71] 2011
90
(age 24–82)
Case
series IV L-PRP
3 L-PRP injections at
3-week interval; before the
injection: Ca-chloride was
added to activate platelets;
knee articular damage:
grades 0–4 of
Kellgren-Lawrence scale.
Improvement at 24 months
from baseline in IKDC,
objective and subjective, and
EQ VAS; worsening of all
scores between 12 and 24
months.
Napolitano
et al. [72] 2012
27
(age 18–81)
Case
series IV L-PRP
3 infiltrations of PRP at
weekly intervals; calcium
gluconate 10% was added;
knee articular damage:
chondropathy (Outerbridge
1-2), grades 1–3 of
Kellgren-Lawrence scale.
Improvement at 6 months
from baseline in Numerical
Rating Scale (NRS) for
subjective measurement of
pain and the WOMAC index
for patients with knee arthritis
and cartilage disease.
Gobbi et al.
[74] 2012
50
(age 32–60)
Case
series IV L-PRP
2 infiltrations of PRP at 1
month interval; articular
damage: grades 1–3 of
Kellgren-Lawrence scale.
Improvement at 6 and 12
months from baseline in VAS
for pain, IKDC subjective and
objective score, KOOS Tegner
and Marx scores.
Sa´nchez
et al. [80] 2012
40
(age 33–84)
Case
series IV P-PRF
3 infiltrations of PRP at
weekly intervals; Calcium
chloride was added; hip
articular damage: Tonnis
2-3.
Improvement at 6 months
from baseline in VAS,
WOMAC Index, and the
Harris pain subscale; no
significant changes in pain
scores between the 6- to
7-week and 6-month time
points.
Torrero
et al. [73] 2012
30
(age 18–65)
Case
series IV L-PRP
Single intra-articular
injection of PRP; knee
articular damage:
chondropathy (Outerbridge
1–3).
Improvement at 6 months
from baseline in VAS and
KOOS.
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PRP and intra-articular injections for cartilage pathology: case series
Authors Year
Number of
cases
(age and
range in y)
Study Level ofevidence
Type of
PRP Procedure and observations Clinical results
Jang et al.
[77] 2013
90
(age 32–85)
Case
series IV L-PRP
PRP obtained through
Magellan Autologous
Platelet Separator; knee
articular damage:
Kellgren-Lawrence Grade
1–3.
Improvement at 6 months
from baseline in VAS and
IKDC score; worsening from
6 to 12 months; negative
correlation with age,
Kellgren-Lawrence grade and
presence of patellofemoral
joint degeneration.
Raeissadat
et al. [76] 2013
60
(mean age 57
± 9)
Case
series IV L-PRP
2 L-PRP injections at
4-week interval; no
exogenous activation; knee
articular damage: grades
1–4 of Kellgren-Lawrence
scale.
Improvement at 6 months
from baseline in WOMAC
Index and the native (Farsi)
edition of the SF-36
questionnaire (physical and
mental).
Halpern
et al. [75] 2013
15
(mean age 54
age 30–70)
Case
series IV P-PRF
1 PRP injection (Cascade
system); knee articular
damage: grades 0–2 of
Kellgren-Lawrence scale.
Improvement at 12 months
from baseline in VAS and
WOMAC Index.
Gobbi et al.
[79] 2014
119
(age 40–65)
Case
series IV P-PRP
3 PRP injections at a
monthly interval; articular
damage: Kellgren-Lawrence
Grade 1-2; 50 cases received
a second cycle at the
completion of 1 year.
Improvement at 24 months
from baseline in VAS, KOOS,
Tegner and Marx scores;
tendency of worsening from
12 to 24 months; at 18 months,
greater improvement in
patients who received the
second cycle.
Mangone
et al. [78] 2014
72
(age 52–82)
Case
series IV L-PRP
3 L-PRP injections at
3-week interval; knee
articular damage:
Kellgren-Lawrence Grade
2-3.
Improvement at 12 months
from baseline in WOMAC
index , VAS at rest, and VAS in
movement; WOMAC index
improved only in the first 3
months.
y = years; PRP = Platelet-Rich Plasma; P-PRP = Pure PRP, with a low content of leukocyte; L-PRP = Leukocyte rich PRP; P-PRF = Pure Platelet-Rich Fibrin.
were confirmed in a subsequent study with a longer follow-
up [71]. The authors confirmed the short-term efficacy of
PRP injections.They also showed that all the evaluated scores
worsened from 12 to 24 months, even though a positive effect
was still detectable. Indeed at 24 months clinical parameters
were still higher with respect to those measured as basal val-
ues. Following these observations, the authors hypothesized
a role of PRP in temporarily reducing the synovial membrane
hyperplasia andmodulating the cytokine level in the arthritic
joint, rather than a long lasting chondroregenerative and
chondroprotective effect.
Similarly to these studies, in 2012 Napolitano et al. [72]
showed decrease of pain and functional improvements at 6
months at the WOMAC (Western Ontario and McMaster
Universities Arthritis Index) score after 3 L-PRP injections
in a group of 27 patients with knee OA (Kellgren and
Lawrence 1–3) and knee cartilage disease (Outerbridge 1-2).
In the same year, Torrero et al. [73] observed a similar trend
of functional recovery at the VAS and KOOS scores after
a single L-PRP injection in a group of 30 patients affected
by knee chondropathy (Outerbridge 1–3) and Gobbi et al.
[74] described improvement up to 1 year from a cycle of 2
PRP injections in 50 active patients with low to intermediate
grade knee OA (Kellgren-Lawrence 1–3). In Gobbi’s study,
a peculiar feature was that half of the patients underwent a
previous arthroscopic treatment (shaving or microfracture),
but this aspect did not influence the final results after the
PRP injections. More recently, in 2013, Halpern et al. [75]
observed pain reduction and functional improvement at 6
months and 1 year from baseline (at the VAS and WOMAC
scores) in a group of 15 patients with low grade knee OA
(Kellgren-Lawrence 0–2) and they were even able to show
at MRI no further cartilage degeneration at the end of the
study in 73% of their patients. In the same year, Raeissadat
in et al. [76] showed a beneficial clinical effect after 6 months
at the SF-36 (Short Form-36) and in the WOMAC question-
naires in patients affected by knee OA ranging from low to
advanced grades. Similarly to other previous studies, these
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Table 3: Comparative studies concerning PRP intra-articular injections for cartilage pathology.
PRP and intra-articular injections for cartilage pathology: comparative studies
Authors Year
Number of
cases
(age and
range in y)
Study Level ofevidence
Type of
PRP Procedure and observations Clinical results
Sa´nchez
et al. [81] 2008
30
(mean age
63 ± 8)
Observational
retrospective
cohort study
III P-PRP
3 PRGF injections at 1-week
interval; control group:
HMW-HA (30 pts); knee
articular damage: Ahlba¨ck
grades 1–4.
Better improvement of
PRGF group at 5 weeks in
WOMAC index.
Kon et al.
[82] 2011
50
(age 30–81)
Prospective
comparative
study
II L-PRP
3 L-PRP injections at
2-week interval; before the
injection: Ca-chloride was
added to activate platelets;
control group: HMW-HA
(50 pts), LMW-HA (50 pts);
knee articular damage:
grades 0–4 of
Kellgren-Lawrence scale.
Better improvement of PRP
group at 6 months in IKDC
and EQ VAS scores; better
results in subgroup of
patients with cartilage
degeneration; worsening
from 2 to 6 months
subgroup in patients with
advanced OA; no difference
between PRP and control
groups in patients over 50
years.
Li et al. [83] 2011 15(age 36–76)
Randomized
prospective
study
II L-PRP
3 PRP injections at 3-week
interval; before the
injection: Ca-chloride was
added to activate platelets;
control group: sodium
hyaluronate (LMW-HA)
(15 pts).
No difference in IKDC
score, WOMAC score, and
Lequesne index between 2
groups within 4 months;
better improvement of PRP
group at 6 months.
Filardo et al.
[67] 2012
54
(mean age 55;
age 18–80)
Randomized
double blind
prospective
comparative
study
I L-PRP
3 L-PRP injections at
1-week interval; control
group: HMW-HA (55 pts);
knee articular damage:
grades 0–4 of
Kellgren-Lawrence scale.
Improvement at 12 months
from baseline in IKDC,
KOOS, EQ-VAS, and
Tegner for both groups; no
differences between PRP
group and controls; trend
toward better results for the
PRP group in patients with
less degenerated joints.
Spakova´
et al. [84] 2012
60
(mean age
53 ± 12)
Prospective
cohort study II L-PRP
3 PRP injections; control
group: HA.
Better improvement of PRP
group at 6 months in
Numerical Rating Scale
(NRS) and the WOMAC
index.
Sa´nchez
et al. [86] 2012
79
(mean age
60 ± 8)
Randomized
controlled trial I P-PRP
3 P-PRP injections at
1-week interval; control
group: HMW-HA (74 pts);
knee articular damage:
Ahlba¨ck grade I–III.
Better improvement of PRP
group at 24 weeks in the
percentage of patients
having a 50% decrease in
WOMAC pain subscale;
trend toward better
improvement (not
significant) of PRP group in
scores on the WOMAC
subscales for stiffness and
physical function, in
Lequesne index, in the
percentage of
OMERACT-OARSI
responders, and in the
amount of acetaminophen
in mg/day.
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PRP and intra-articular injections for cartilage pathology: comparative studies
Authors Year
Number of
cases
(age and
range in y)
Study Level ofevidence
Type of
PRP Procedure and observations Clinical results
Cerza et al.
[85] 2012
60
(mean age
66 ± 11)
Randomized
controlled trial I P-PRP
4 PRP injections at 1-week
interval; control group:
LMW-HA (60 pts).
Better improvement of PRP
group at 24 weeks in
WOMAC scores; no
correlation with the grade
of gonarthrosis.
Mei-Dan
et al. [92] 2012
15
(mean age
43 ± 18)
Randomized
controlled trial II P-PRP
3 PRGF injections at
2-week interval; control
group: HMW-HA (15
lesions; 1-week interval);
ankle articular damage:
Ferkel grade 1–3
osteochondral lesions.
Better improvement of PRP
group at 28 weeks in
AOFAS Ankle-Hindfoot
Scale (AHFS), VAS for
pain, stiffness, and
function, subjective global
function scores.
Vaquerizo
et al. [87] 2013
48
(age 62 ± 7)
Randomized
controlled trial I P-PRP
3 P-PRP injections at
1-week interval; control
group: HMW-HA (48 pts; 1
single injection); knee
articular damage: grades
2–4 of Kellgren-Lawrence
scale.
Better improvement of PRP
group at 48 weeks in
WOMAC index, Lequesne
index and
OMERACT-OARSI
responders.
Say et al.
[88] 2013
45
(mean age 55)
Prospective
study II P-PRP
1 P-PRP injections; control
group: HA (45 pts; 3
injections at 1-week
interval).
Better improvement of PRP
group at 6 months in
KOOS and VAS for pain.
Patel et al.
[89] 2013
52
(group A; age
33–80)
50
(group B; age
34–70)
Randomized
controlled trial I P-PRP
Group A (52 knees): single
injection of PRP; group B
(50 knees): 2 injections of
PRP at 3-week interval;
group C (46 knees): single
injection of normal saline;
knee articular damage:
Ahlba¨ck grade I-II.
Better improvement of PRP
groups at 6 months in
WOMAC, VAS and overall
satisfaction with the
procedure; no difference
between group A and B;
slight worsening from 3 to
6 months.
Hart et al.
[90] 2013
50
(age 31–75)
Randomized
controlled trial I P-PRP
9 PRP injections during 1
year; control group (50 pts):
1% mesocain; knee articular
damage: Grade II
(fibrillation), Grade III
(fissuring and
fragmentation, but no bone
exposed).
Better improvement of PRP
groups at 12 months in
Lysholm, Tegner, IKDC,
and Cincinnati scores.
Battaglia
et al. [91] 2013
50
(age 25–76)
Randomized
controlled trial I L-PRP
3 PRP injections at 1-week
interval; control group:
HMW-HA (50 pts); hip
articular damage: grades
2–4 of Kellgren-Lawrence
scale.
No difference at 12 months
between the groups in
Harris Hip Score (HHS),
NSAID consumption and
VAS.
y = years; PRP = Platelet-Rich Plasma; P-PRP = Pure PRP, with a low content of leukocyte; L-PRP = Leukocyte rich PRP; P-PRF = Pure Platelet-Rich Fibrin;
LMWHA = Low Molecular Weight Hyaluronic Acid; HMW-HA = High Molecular Weight Hyaluronic Acid; pts = patients; PRGF = “Preparation Rich In
Growth Factors” or Plasma-Rich Growth Factors or Platelet Rich Growth Factor with a very low/absent content of leukocytes.
authors also demonstrated an improvement in pain, stiffness,
and functional capacity, with reverse relationship between
patient’s age and degree of pain reduction. Nevertheless,
they were not able to observe any correlation between the
symptoms improvement and the patients’ weight, the grade of
osteoarthritis or the platelet concentration (ranging in their
study from 2.4 to 8.6 times). On the contrary, the study of
Jang et al. [77] pointed out the negative correlation between
patellofemoral joint degeneration and poorer outcomes,
along with symptoms worsening after 1 year from the first
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injection.They also observed a relapse of pain approximately
9months after the procedure and an adverse effect of patient’s
age in the final outcome.
In 2014, a study ofMangone et al. [78] again confirmed the
value of L-PRP injections in a group of 79 patients selectively
affected by intermediate grade knee OA (Kellgren-Lawrence
1–3). They showed improvement up to 1 year after the end
of the treatment in WOMAC scale, VAS at rest, and VAS
in movement. The treatment involved 3 PRP injections at
3-week interval. They outlined the role of PRP as a second
approach to the treatment of knee OA due to the still high
costs of this procedure compared to that of traditional HA
therapy. An original observation came the same year from a
study by Gobbi et al. [79]. They evaluated a group of patients
after 2 years. They indicated a greater improvement of the
clinical scores when the cycle of PRP injections was repeated
after 1 year. However, they also perceived a decline in the
performances at the end of follow-up.This was the first study
supporting the value of a cyclical treatment with PRP.
PRP injections have been also applied to treat hip OA
with limited results. In a preliminary study by Sa´nchez et al.
[80], the outcomes were less satisfactory: 57% only of patients
reported a clinically relevant relief of pain. An improvement
in the Harris score, WOMAC pain score, and VAS scale was
detected at 6 weeks but no further changes were observed.
From these case series, PRP appears to have a potential for
improving knee function and quality of life of patients suffer-
ing from chondropathy or initial OA, by means of reducing
the inflammation and, in a lesser extent, the degenerative
articular processes. Nevertheless, some suggestions can be
proposed; indeed, a better result seems to be related to
(i) younger patients,
(ii) lower degree of cartilage degeneration,
(iii) male gender,
(iv) low BMI,
(v) short-term follow-up (themedian duration of the effi-
cacy of PRP injections being estimated at 9 months),
(vi) protocols implying a repeated course of injections
(i.e., after 1 year).
However, if the analysis of the case series enlightens some
limits in the use of PRP injections, more promising signs
come from the analysis of comparative studies regarding the
benefit of PRP as a conservative therapy for chondropathy or
initial OA. In fact, PRP has been matched with viscosupple-
mentation, local anesthetics, and saline solution to assess its
possible positive effect.
One of the first contributions came from the study
of Sa´nchez et al. in 2008 [81]. The authors compared 3
injections of a single-spinning P-PRP (“preparation rich in
growth factors,” PRGF) with those of a low molecular weight
hyaluronic acid (LMW-HA) at a short-term follow-up. The
WOMAC score showed clinical improvement: 5 weeks after
the third injection significant pain reduction was recorded in
33% of PRP group while only in 10% of the control one.
Subsequently, in a complex multicenter study of Kon
et al. in 2011 [82], L-PRP injections were compared with
low molecular weight (LMW) and high molecular weight
(HMW) hyaluronic acid (HA) administrations. At 2 months,
no difference was detected between PRP and the HA, and
worst results were described for patients treated with HMW-
HA. Nevertheless, the authors observed at 6 months a
clear positive effect of PRP, while LMW-HA treated patients
showed a worsening of the performances. This effect was
more evident in young patients and in the presence of early
cartilage degeneration, as demonstrated by an improvement
of symptoms and function at the IKCD score and at the EQ-
VAS score. They did not find superior benefit of PRP with
regards to HA in older patients (more than 50 years old) and
in the presence of advanced OA. The patients with early OA
treated with PRP displayed an “intermediate” effect, having
stable score at 2 and 6 months, while the LMW-HA group
worsened. Again, these results supported the hypothesis of
an efficacy of PRP injections in reducing pain and symptoms
and recovering articular function in patients affected by
knee degeneration. This was particularly evident in patients
younger than 50 years and affected by early stage of the
pathology. In this subgroup of patients, these effects were
longer (up to 6months) than thewell-known transient results
of the HA injections. These observations were confirmed in
a blinded randomized study from the same authors at 1-
year follow-up [67]. They compared L-PRP injections with
HMW-HA and both groups showed improvement in the
performances at the clinical scores (IKDC, KOOS, EQ-VAS,
Tegner), although no significant differences were observed at
12 months of follow-up. Nevertheless, a trend toward a better
result was observed in the PRP group in the presence of early
joint degeneration.
The positive longer effect of PRP injections was also
confirmed in the randomized prospective study by Li et al.
[83]. They matched PRP with sodium hyaluronate in a small
group of patients with knee articular cartilage degeneration.
Even if similar outcomes where observed at 4 months in
both groups, significant differences in IKDC score, WOMAC
score, and Lequesne index were shown at 6 months. This
confirmed the more durable improvement of PRP compared
to that of HA. The study of Spakova´ et al. [84] further
strengthened these assumptions. In particular, by comparing
PRP with HA, they did not notice similar early outcomes
between the two groups but a constant superiority of the
outcomes of patients treated by PRP injections at both 3 and 6
months of follow-up. Similarly, the study of Cerza et al. [85] in
2012 demonstrated that a formulation of P-PRP (autologous
conditioned plasma, ACP) was superior to HA at any time
point over 24 weeks of follow-up. The authors did not even
noticed any worsening of the PRP effect in the presence of
severe gonarthrosis (Kellgren-Lawrence grade III), while the
outcomes of the HA control group were strongly influenced
by the degree of osteoarthritis.
Conversely, in the same year, a randomized study from
Sa´nchez et al. [86] failed to demonstrate a statistically sig-
nificant superiority in overall knee performances of patients
treated with P-PRP (PRGF) injections, compared to a control
group treated with HMW-HA. The authors found a clear
difference only in the evaluation of pain, observing a 50%
decrease in the WOMAC pain subscale from baseline to
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6 months in approximately 40% of patients treated with
P-PRP and in 24% of patients treated with HMW-HA.
Nevertheless, using the same PRP preparation (PRFG) of
the study of Sa´nchez et al., a recent comparative study with
HMW-HA has given surprising results. Indeed, Vaquerizo
et al. [87] observed an improvement in both pain and physical
performances (i.e., stiffness and physical function) at 24
and 48 weeks in patients affected by knee OA of Kellgren-
Lawrence grades 2 to 4. Compared to the study of Sa´nchez
et al., the main differences of the Vaquerizo’s trial were (i) the
HA formulation (a higher HMW-HA), (ii) the inclusion of
patients with higher degree of OA, and (iii) the single HA
injection compared with a cycle of 3 injections on a weekly
basis of PRP.These results seem in accordance with the study
of Kon et al. in 2011 with regards to HMW-HA.They support
a possible biological efficacy of PRP for treatment of knee
OA in a medium to long term follow-up (less than 1 year).
Moreover, a recent study of Say et al. [88] showed that even
a single dose of P-PRP (PRGF) may exert a benefit at the
KOOS and VAS scales when compared to 3 intra-articular
injections of HA in a short-term follow-up (6 months), in
patients affected by bilateral gonarthrosis. This “single-shot
approach” may offer the advantage of a greater safety and
cost-effectiveness compared to the approach with multiple
injections.
PRP has been recently compared to saline solution, as a
placebo, in an interesting study byPatel et al. [89].The authors
investigated also 2 differentmodalities of PRP administration
(1 injection versus 2 injections regimen) in patients with
knee OA (Ahlba¨ck grade 1 and 2). In this randomized
controlled trial, many of the previously reported evidences
about the use of intra-articular PRP were confirmed. Indeed,
the authors found that a statistically significant improvement
was present both with a single dose and with 2 injections of
PRP compared to placebo.They also observed that the effects
were present up to 6 months of follow-up, even though at
the end term evaluation the scores in the PRP groups started
to deteriorate. Furthermore, better outcomes were found in
patients with low grade of articular degeneration (Ahlba¨ck
grade 1). Surprisingly, no correlation of improvement by
means of PRP was found with respect to age, sex, or BMI.
A completely different approach has been used by Hart
et al. [90] in a recent trial investigating the use of intra-
articular PRP versus mesocain injection. The rationale of
their therapeutic design was the cyclical treatment with P-
PRP. In the study, patients underwent 6 injections at 1-week
intervals, treatment interruption for 3 months, and then
three PRP injections at 3-month intervals as a maintenance
dose. This is actually the comparative study dealing with the
highest number of PRP injections. The amazing result is that
the outcomes of such a “PRP loaded” procedure are not so
different from other “more essential” study. Indeed, at 12
months after the end of the PRP treatment, the authors found
an improvement of pain and knee function at the Lysholm,
Tegner, IKDC, and Cincinnati scores, but no significant
influence on cartilage trophism was observed at the MRI. So,
no clear benefit of such a large PRP course was validated.
Few comparative studies, finally, exist in literature regard-
ing the use of intra-articular PRP outside the knee joint, and
their results are promising. Battaglia et al. [91] investigated
the effect of ultrasound-guided PRP injections versus HWM-
HA intra-articular administration for the treatment of hip
OA. They assessed the clinical benefit through the use of
the Harris Hip Score (HHS) and the VAS scale at 1 year.
They observed an improvement up to 6 months, with a
slight decrease from 6 to 12 months, that paralleled the
effect of the HA, and a reduction of the nonsteroidal anti-
inflammatory drugs (NSAID) consumption in the PRP group
in a short-term follow-up. This confirmed the temporary
efficacy of PRP also for the treatment of hip OA. In a different
perspective, Mei-Dan et al. [92] examined the use of PRP
versus HA injections for the nonoperative treatment of talar
osteochondral lesions. At a short-term follow-up (28 weeks),
they found a better improvement of theAnkle-Hindfoot Scale
(AHFS), and VAS scales (for pain, stiffness, and function)
for the PRP-treated group, along with a similar trend for the
subjective global function perceived by the patients. Again,
this work confirmed the superior short-term efficacy of PRP
with respect to HA also for the treatment of talar cartilage
lesions.
Therefore, in the “history so far,” the results of all these
comparative studies offer some basic answers to the sug-
gestions driven by the case series in literature. Indeed,
length of action, grade of OA, age of the patients, safety of
the administration, and superiority of PRP towards LMW-
HA and HMW-HA have been actually clarified. PRP intra-
articular administration appears a relatively safe procedure
with few negligible short-term side effects, as transient joint
pain and effusion. There is also a strong evidence that
(i) PRP injection may exert a positive influence in
patients affected by knee cartilage degeneration and
OA (with a preliminary suggestion, even for talar
osteochondral lesions);
(ii) PRP injection may have a greater and longer effi-
cacy than HA or placebo (saline) administration in
improving pain and articular function;
(iii) the beneficial effect of PRP injection is still temporary
and it could be estimated to last up to 1 year, with a
peak of action detectable at 6 months.
Moreover, the previously mentioned comparative studies
agree with the recent reviews andmeta-analysis fromAbrams
et al. [93], Anitua et al. [94], Chang et al. [95], Dold
et al. [96], Khoshbin et al. [97], Pourcho et al. [98], and
Tietze et al. [99], confirming the safety of PRP injections,
the reduction of pain, the short term clinical benefit for
symptomatic mild to moderate knee OA, and the influence
of the severity of the degenerative process on the response
to the treatment. Indeed, the greatest results are achieved in
young patients affected by lower degree of OA or cartilage
degeneration. This is in accordance with the concept that
all biological therapies are positively influenced by a proper
active microenvironment at the lesion site in order to reach
the higher level of success.
These conclusions suggest that the primary role of PRP
injections has to be found not in a direct stimulation of
chondrocyte anabolic processes, but rather in a temporary
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modulation of joint homeostasis by the anti-inflammatory
effects of PRP. This may lead to a reduction of synovial
hyperplasia and cytokine production (i.e., IL-1b [17]) and,
consequently, to the observed significant improvements of
the clinical outcomes in a short-term follow-up.
Considering all the present evidences, literature does
not justify an indiscriminate practice of PRP injections
as a fist line treatment. The PRP seems to be instead an
ideal candidate for a discriminative usage in the field of
conservative therapy of degenerative chondropathy and mild
OA, addressing specifically to a selected group of patients
less than 50 years old or patients resistant to other current
nonsurgical treatments [78, 95]. With regard to that, the
literature continues to suggest the use of PRP injections in
clinical trials [100], to allow for a deeper comprehension of
the limits and the effectiveness of this therapeutic approach.
Still, in this scenario, some questions remain unsolved.
It is unclear if PRP injection may sustain a substantial effect
beyond the medium-term follow-up (1 year), independently
from the number of doses given to the patients. Furthermore,
the best administration protocol is yet to be determined,
although most of the studies propose a minimal requirement
of 3 doses. Solving these aspects may lead to recommend
a cyclic regimen of treatment in which patients receive
repetitive course of PRP injections (i.e., at 1 year interval) in
order to achieve longer lasting results and to ultimately delay
more invasive surgical treatments.
It is also a matter of debate if PRP may have a secondary
substantial chondroprotective effect toward the progression
of joint degeneration. From the current studies, no clear
evidence of anabolic responses of cartilage tissue has been
observed at the MRI. Nevertheless, the preclinical evidences
suggest that PRP effects seem to “go beyond” a simple anti-
inflammatory action. If this concept will be confirmed in
the future, the clear impact of PRP on the natural history of
degenerative OA will be determined.
No clear consensus exists concerning some secondary
aspects of patient selection, as the influence of BMI and of
sex, even though lowBMI andmale sex seems to lead to better
clinical results.
The better activation method of PRP is unknown. Due
to the differences in the study protocols available, it is
impossible to determine which, if any, activating agent is
preferable. However, a recent report by Textor et al. [101]
has outlined that thrombinmay cause inflammatory cytokine
responses in joints, while no activation or the use of calcium
chloride seems advisable. Moreover, novel approach, as the
photoactivation [102], starts to be popular, even if the value
of these new methods is still investigational.
The concurrent use of other treatment modalities is also
an unclear aspect of the PRP injection approach. Indeed, PRP
has been studied alone, but the combined use of PRP and
other substances with dissimilar biological mechanisms may
constitute a novel field of application, in order to broaden
the indication and the effect of the simple PRP injection.
Recently, the association of PRP and HA injections has been
proposed [103] to modify the altered joint microenviron-
ment of osteoarthritic knee. Furthermore, the percutaneous
MSC injections have been recently associated with PRP in
a promising trial by Pak et al. [104, 105]. They obtained
MSC in the form of a stromal vascular fraction of adi-
pose tissue. They injected a mixture composed by the cell
concentrate, PRP, hyaluronic acid, and calcium chloride,
obtaining promising results in patients with chondromalacia
patellae. Further studies will clarify the value of this appealing
therapeutic perspective.
Finally, the issue about PRP preparation method and the
presence of leukocyte is a challenging topic.The controversial
role of leukocyte originates from the observation that white
cells may release inflammatory mediators, proteases, and
reactive oxygen species in the intra-articular space, causing
transient joint inflammation that may hamper the effect
of PRP. From a different perspective, white cells, especially
peripheral bloodmononuclear cells (lymphocytes andmono-
cytes) may exert a positive effect by means of releasing
anabolic cytokines as IL-6 as well as proteins and enzymes
involved in the prevention of joint infection [31, 106]. A
prospective study of Filardo et al. [107] compared P-PRP
(PRGF) and L-PRP in 144 patients affected by knee OA.They
failed to find a significant difference in the clinical outcomes
(KDC, EQ VAS and Tegner scores) up to 12 months, besides
the occurrence of minor adverse events as pain and swelling
in the presence of leukocytes. Nevertheless, recent in vitro
evidences [108] have questioned this result pointing out the
upregulation of proinflammatory factors, (IL-1beta, IL-8 and
FGF-2) and the downregulation of HGF and TIMP-4 in
synoviocytes in the presence of L-PRP. Therefore, the quest
for the best PRP formulation is still open.
4. Conclusion
The review of the literature, along with the new in vitro and
preclinical perspectives, gives PRP a fascinating biological
possibility as a therapeutic approach for cartilage pathology.
Certainly, more works has to be done in order to establish
common guidelines. At this regard, high quality trials will
help to clarify some of the open questions about the specific
use of PRP as (i) a component of the surgical management
of cartilage lesions, as well as (ii) a nonoperative injective
modality for treating low grade osteoarthritis and cartilage
degeneration. With regard to that, some new intuitions may
be useful in the future.
In the field of surgery, a recent study outlined that the
activity of PRP may be enhanced in presence of specific
biphasic tridimensional porous scaffold made of collagen
type I and glycosaminoglycan [109]. Indeed, this combination
led to a spontaneous activation of PRP without the need
of thrombin or any other activating factors and a sustained
release of growth factors as PDGF, FGF-2, andTFG-beta.This
might also represent an increasing evidence for the use of
scaffold carrying PRP for cartilage healing.
It is, however, from the study of synergistic approaches
that some attractive proposal may be suggested. A new
perspective is, indeed, the modulation of PRP by means of
other substances that may hasten the positive anabolic effect
of PRP itself. In that, the intuitions of Jonny Huard and
his research group about the use of PRP and losartan to
improvemuscle healing have been fundamental [110]. Indeed,
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the association of PRP and anti-VEGF antibody seems
promising for cartilage regeneration, considering the well-
known effect of VEFG in promoting hypervasculariza-
tion and stimulating angiogenesis [11, 111]. The intravenous
administration of a monoclonal anti-VEGF antibody (beva-
cizumab) has already given promising results in preclinical
rabbit model [112]. Moreover, a recent preclinical study has
shown the positive effect of a VEGF antagonist combined
with PRP in improving cartilage repair increasing type II
collagen production in a rat model [113].
The local delivery of PRP associatedwith systemic admin-
istration of G-CSF seems also a promising horizon. The
theoretical advantage of stem cell mobilization by means
of subcutaneous G-CSF injection in association with PRP
administration has been recently proposed by Turajane et al.
[58] in an in-vitro study. They showed that the addition of
PRP and G-CSF stimulated peripheral blood stem cells to
proliferate toward a chondrocyte phenotype. Furthermore,
a previous study by Deng et al. have already outlined the
potential of G-CSF-mobilized peripheral blood stem cells
in promoting articular regeneration in OA in a preclinical
rat model [59]. These observations suggest new therapeutic
potential approaches for cartilage repair bymeans of systemic
G-CSF and local PRP injection for the treatment of low-grade
osteoarthritis.
So, the story “goes on” and, while new clinical studies
will be proposed, preclinical evidences will emerge with new
fascinating proposals: the future directions of PRP in the
field of cartilage therapy is really a whole new world to be
discovered.
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